J Korean Med Assoc Search

CLOSE


J Korean Med Assoc > Volume 52(1); 2009 > Article
Kim: Sarcoidosis

Abstract

Sarcoidosis is a systemic granulomatous disease of unknown etiology that mainly develops between 25 and 40 years of age and primarily affects the lungs and the lymphatic system. Generally accepted pathogenic hypothesis is that certain environmental agents could promote sarcoidosis in genetically susceptible hosts. The characteristic lesion of sarcoidosis is a noncaseating granuloma that consist of epithelioid cells and T lymphocytes. Diverse clinical courses are observed according to the epidemiologic factors, involved organs, and disease severity. Spontaneous remissions occur in approximately two thirds of patients, but the course is chronic or deteriorative in 10 to 30%. Mortality, ranging between 1 and 5%, is mostly related to progressive respiratory insufficiency, or central nervous system or myocardial involvement. The mainstay of treatment for sarcoidosis is systemic corticosteroid administration. However, the indication, optimal dose, and duration of corticosteroid therapy continue to be controversial.

References

1. Hutchinson J. In: Hutchinson J, editor. Case of livid papillary psoriasis. Illustrations of clinical surgery 1877;vol.1:London: J&A Churchill. 42-43.

2. Boeck C. Multiple benign sarkoid of the skin. Journal of Cutaneous and Genitourinary Disease 1899;17:543-550.

3. Hillerdal G, Nou E, Osterman K, Schmekel B. Sarcoidosis: epidemiology and prognosis. A 15-year European study. Am Rev Respir Dis 1984;130:29-32.

4. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997;336:1224.

5. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-241.

6. Henke CE, Henke G, Elveback LR, Beard CM, Ballard DJ, Kurland LT. The epidemiology of sarcoidosis in Rochester, Minnesota: a population-based study of incidence and survival. Am J Epidemiol 1986;123:840-845.

7. James DG, Hosoda Y. In: James DG, editor. Epidemiology. Sarcoidosis and other granulomatous disorders 1994;New York: Marcel Dekker. 729-743.

8. Teirstein AS, Lesser M. In: Fanburg BL, editor. Worldwide distribution and epidemiology of sarcoidosis. Sarcoidosis and other granulomatous diseases of the lung 1983;New York: Marcel Dekker. 101-134.

9. Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us? Clin Chest Med 1997;18:681-694.

10. Hosoda Y. In: Grassi C, Rizzato G, Pozzi E, editor. Epidemiology of sarcoidosis: State-of-the-art. Proceedings of the 11th World Congress on sarcoidosis and other granulomatous disorders 1988;Amsterdam: Elsevier Science. 279-290.

11. Bresnitz EA, Strom BL. Epidemiology of sarcoidosis. Epidemiol Rev 1983;5:124-156.

12. Scientific committee in korean academy of tuberculosis and respiratory disease. National survey of sarcoidosis in korea. Tuberc Respir Dis 1992;39:453-473.

13. Kim DS, Ahn JJ. Sarcoidosis in korea. Tuberc Respir Dis 2000;49:274-280.

14. Verleden GM, du Bois RM, Bouros D, Drent M, Millar A, Muller-Quernheim J, Semenzato G, Johnson S, Sourvino G, Olivier D, Pietinalho A, Xaubet A. Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J Suppl 2001;32:17s-29s.

15. du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med 2003;253:4-17.

16. Conron M, Du Bois RM. Immunological mechanisms in sarcoidosis. Clin Exp Allergy 2001;31:543-554.

17. Boros DL. Experimental granulomatosis. Clin Dermatol 1986;4:10-21.

18. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981;305:429-434.

19. Semenzato G, Pezzutto A, Chilosi M, Pizzolo G. Redistribution of T lymphocytes in the lymph nodes of patients with sarcoidosis. N Engl J Med 1982;306:48-49.

20. Agostini C, Trentin L, Zambello R, Bulian P, Siviero F, Masciarelli M, Festi G, Cipriani A, Semenzato G. CD8 alveolitis in sarcoidosis: incidence, phenotypic characteristics, and clinical features. Am J Med 1993;95:466-472.

21. Konishi K, Moller DR, Saltini C, Kirby M, Crystal RG. Spontaneous expression of the interleukin 2 receptor gene and presence of functional interleukin 2 receptors on T lymphocytes in the blood of individuals with active pulmonary sarcoidosis. J Clin Invest 1988;82:775-781.

22. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985;75:1488-1495.

23. Baughman RP, Strohofer SA, Buchsbaum J, Lower EE. Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis. J Lab Clin Med 1990;115:36-42.

24. Moller DR, Forman JD, Liu MC, Noble PW, Greenlee BM, Vyas P, Holden DA, Forrester JM, Lazarus A, Wysocka M, Trinchieri G, Karp C. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996;156:4952-4960.

25. Agostini C, Trentin L, Facco M, Sancetta R, Cerutti A, Tassinari C, Cimarosto L, Adami F, Cipriani A, Zambello R, Semenzato G. Role of IL-15, IL-2, and their receptors in the development of T cell alveolitis in pulmonary sarcoidosis. J Immunol 1996;157:910-918.

26. Kreipe H, Radzun HJ, Heidorn K, Barth J, Kiemle-Kallee J, Petermann W, Gerdes J, Parwaresch MR. Proliferation, macrophage colony-stimulating factor, and macrophage colonystimulating factor-receptor expression of alveolar macrophages in active sarcoidosis. Lab Invest 1990;62:697-703.

27. Rosen Y. In: Dail DH, Hammer SP, editor. Sarcoidosis. Pulmonary Pathology 1994;2nd ed. New York: Springer-Verlag. 13-645.

28. Colby TV, Carrington CB. In: Thurlbeck WM, Churg AM, editor. Interstitial lung diseases. Pathology of the lung 1995;New York: Thieme Medical Publishers. 589-737.

29. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-755.

30. Bein ME, Putman CE, McLoud TC, Mink JH. A reevaluation of intrathoracic lymphadenopathy in sarcoidosis. AJR Am J Roentgenol 1978;131:409-415.

31. Rockoff SD, Rohatgi PK. Unusual manifestations of thoracic sarcoidosis. AJR Am J Roentgenol 1985;144:513-528.

32. Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA, DePalo L, Hunninghake G, Iannuzzi MC, Johns CJ, McLennan G, Moller DR, Newman LS, Rabin DL, Rose C, Rybicki B, Weinberger SE, Terrin ML, Knatterud GL, Cherniak R. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-1889.

33. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983;52:525-533.

34. Romer FK. Presentation of sarcoidosis and outcome of pulmonary changes. Dan Med Bull 1982;29:27-32.

35. Reich JM, Johnson RE. Course and prognosis of sarcoidosis in a nonreferral setting. Analysis of 86 patients observed for 10 years. Am J Med 1985;78:61-67.

36. Siltzbach LE. Sarcoidosis: clinical features and management. Med Clin North Am 1967;51:483-502.

37. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997;111:623-631.

38. Hunninghake GW, Gilbert S, Pueringer R, Dayton C, Floerchinger C, Helmers R, Merchant R, Wilson J, Galvin J, Schwartz D. Outcome of the treatment for sarcoidosis. Am J Respir Crit Care Med 1994;149:893-898.

39. Chappell AG, Cheung WY, Hutchings HA. Sarcoidosis: a long-term follow up study. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:167-173.

40. Pietinalho A, Ohmichi M, Lofroos AB, Hiraga Y, Selroos O. The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five-year study of biopsyproven cases. Sarcoidosis Vasc Diffuse Lung Dis 2000;17:158-166.

41. Lynch JP 3rd, Sharma OP, Baughman RP. Extrapulmonary sarcoidosis. Semin Respir Infect 1998;13:229-254.

42. Yamaguchi M, Hosoda Y, Sasaki R, Aoki K. Epidemiological study on sarcoidosis in Japan. Recent trends in incidence and prevalence rates and changes in epidemiological features. Sarcoidosis 1989;6:138-146.

43. Iwai K, Sekiguti M, Hosoda Y, DeRemee RA, Tazelaar HD, Sharma OP, Maheshwari A, Noguchi TI. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994;11:26-31.

44. James DG, Epstein WL. In: James DG, editor. Cutaneous sarcoidosis. Sarcoidosis and other granulomatous disorders 1994;New York: Marcel Dekker. 311-322.

45. Gilman MJ, Wang KP. Transbronchial lung biopsy in sarcoidosis. An approach to determine the optimal number of biopsies. Am Rev Respir Dis 1980;122:721-724.

46. Costabel U. Sensitivity and specificity of BAL findings in sarcoidosis. Sarcoidosis 1992;9:211-214.

47. Scadding JG. Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation. Br Med J 1961;2:1165-1172.

48. Siltzbach LE, James DG, Neville E, Turiaf J, Battesti JP, Sharma OP, Hosoda Y, Mikami R, Odaka M. Course and prognosis of sarcoidosis around the world. Am J Med 1974;57:847-852.

49. Lynch JP 3rd, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997;18:755-785.

50. Gibson GJ, Prescott RJ, Muers MF, Middleton WG, Mitchell DN, Connolly CK, Harrison BD. British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment. Thorax 1996;51:238-247.

51. Johns CJ, Schonfeld SA, Scott PP, Zachary JB, MacGregor MI. Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications. Ann N Y Acad Sci 1986;465:702-712.

52. Yamamoto M, Saito N, Tachibana T. In: Chretien J, Marsac J, Saltiel JC, editor. Effects of an 18 month corticosteroid therapy to stage I and stage II sarcoidosis patients (control trial). Sarcoidosis and other granulomatous disorders 1980;Paris: Pergamon Press. 470-474.

53. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States 1979-1991: an analysis of multiple-cause mortality data. Am J Med 1996;100:423-427.

54. Perry A, Vuitch F. Causes of death in patients with sar-coidosis. A morphologic study of 38 autopsies with clinico-pathologic correlations. Arch Pathol Lab Med 1995;119:167-172.

55. Sharma OP. Pulmonary sarcoidosis and corticosteroids. Am Rev Respir Dis 1993;147:1598-1600.

56. Takada K, Ina Y, Noda M, Sato T, Yamamoto M, Morishita M. The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 1993;46:359-366.

57. Viskum K, Vestbo J. Vital prognosis in intrathoracic sarcoidosis with special reference to pulmonary function and radiological stage. Eur Respir J 1993;6:349-353.

58. Vestbo J, Viskum K. Respiratory symptoms at presentation and long-term vital prognosis in patients with pulmonary sarcoidosis. Sarcoidosis 1994;11:123-125.

59. Huang CT, Heurich AE, Sutton AL, Lyons HA. Mortality in sarcoidosis. A changing pattern of the causes of death. Eur J Respir Dis 1981;62:231-238.

60. Baughman RP, Winget DB, Bowen EH, Lower EE. Predicting respiratory failure in sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 1997;14:154-158.

61. Löfgren S. Erythema nodosum: studies on etiology and pathogenesis in 185 adult cases. Acta Med Scand 1946;124:1-197.

62. James DG, Neville E, Siltzbach LE. A worldwide review of sarcoidosis. Ann N Y Acad Sci 1976;278:321-334.

63. Glennas A, Kvien TK, Melby K, Refvem OK, Andrup O, Karstensen B, Thoen JE. Acute sarcoid arthritis: occurrence, seasonal onset, clinical features and outcome. Br J Rheumatol 1995;34:45-50.

64. Berlin M, Fogdell-Hahn A, Olerup O, Eklund A, Grunewald J. HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 1997;156:1601-1605.

65. Gran JT, Bohmer E. Acute sarcoid arthritis: a favourable outcome? A retrospective survey of 49 patients with review of the literature Scand J Rheumatol 1996;25:70-73.

66. Rizzato G, Montemurro L. In: James DG, editor. The locomotor system. The locomotor system 1994;New York: Marcel Dekker. 349-373.

67. Ward K, O'onnor C, Odlum C, Fitzgerald MX. Prognostic value of bronchoalveolar lavage in sarcoidosis: the critical influence of disease presentation. Thorax 1989;44:6-12.

68. Lofgren S. The concept of erythema nodosum revised. Scand J Respir Dis 1967;48:348-353.

69. James D. Sarcoidosis of the skin. Semin Respir Med 1992;13:422-441.

70. Chapelon C, Ziza JM, Piette JC, Levy Y, Raguin G, Wechsler B, Bitker MO, Bletry O, Laplane D, Bousser MG, et al. Neurosarcoidosis: signs, course and treatment in 35 confirmed cases. Medicine (Baltimore) 1990;69:261-276.

71. Rizzato G, Colombo P. Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. Sarcoidosis Vasc Diffuse Lung Dis 1996;13:167-172.

72. Israel HL, Karlin P, Menduke H, DeLisser OG. Factors affecting outcome of sarcoidosis. Influence of race, extrathoracic involvement, and initial radiologic lung lesions. Ann N Y Acad Sci 1986;465:609-618.

73. Adams J. Hypercalcemia and hypercalcuria. Semin Respir Med 1992;13:402-410.

74. Rizzato G, Fraioli P, Montemurro L. Nephrolithiasis as a presenting feature of chronic sarcoidosis. Thorax 1995;50:555-559.

75. Johnson D, Yamakido M, O S. Musculoskeletal involvement in sarcoidosis. Semin Respir Med 1992;13:415-419.

76. Rohatgi P. Osseous sarcoidosis. Semin Respir Med 1992;13:468-488.

77. Sartoris DJ, Resnick D, Resnik C, Yaghmai I. Musculoskeletal manifestations of sarcoidosis. Semin Roentgenol 1985;20:376-386.

78. Scott TF. Neurosarcoidosis: progress and clinical aspects. Neurology 1993;43:8-12.

79. Agbogu BN, Stern BJ, Sewell C, Yang G. Therapeutic considerations in patients with refractory neurosarcoidosis. Arch Neurol 1995;52:875-879.

80. Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003;361:1111-1118.

81. Baughman RP. Therapeutic options for sarcoidosis: new and old. Curr Opin Pulm Med 2002;8:464-469.

82. Paramothayan S, Jones PW. Corticosteroid therapy in pulmonary sarcoidosis: a systematic review. JAMA 2002;287:1301-1307.

83. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999;115:1158-1165.

Figure 1
Chest radiographic staging of sarcoidosis.
(A) Stage I. The posteroanterior film shows bilateral hilar lymphadenopathy with clear lung fields.
(B) Stage II. The posteroanterior film shows bilateral hilar lymphadenopathy associated with parenchymal infiltration.
(C) StageIII.The posteroanterior film shows parenchymal infiltration without hilar lymphadenopathy, but no obvious fibrotic changes.
(D) StageIV. The posteroanterior film shows predominantly upper lobe fibrotic abnormalities with hilar retraction, coarse fibrotic masses (mostly on the left), and bibasal compensatory emphysema (secondary to the loss of upper lobe volume).
jkma-52-41-g001-l.jpg
Figure 2
High-resolution computed tomographic section showing widespread micronodules.
jkma-52-41-g002-l.jpg
Table 1
Chest radiographic staging
jkma-52-41-i001-l.jpg
Table 2
Recommended inital evaluation of patients with sarcoidisis
jkma-52-41-i002-l.jpg


ABOUT
ARTICLE CATEGORY

Browse all articles >

ARCHIVES
FOR CONTRIBUTORS
Editorial Office
37 Ichon-ro 46-gil, Yongsan-gu, Seoul
Tel: +82-2-6350-6562    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2024 by Korean Medical Association.

Developed in M2PI

Close layer
prev next